Journal of Clinical Case Reports

Reduction of Pericardial Effusion in Patients with Advanced Non-Small Cell Lung Cancer Treated by Nivolumab

Abstract

Cai Z, Tian X and Dong L

Nivolumab is an immune checkpoint inhibitor used to treat various advanced malignancies including metastatic non-small cell lung cancer. The side effects of immunotest inhibitors are different from traditional cytotoxic chemotherapy and pericardial effusion is one of the adverse effects of immunotherapy. However, here we present a 59-year-old male with advanced non-small cell lung cancer (NSCLC) treated with nivolumab who successfully managed reduction of pericardial effusion in patients treated by Nivolumab after 11 cycles. During the treatment, he underwent only one pericardial puncture and drainage of pericardial effusion.